A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MBRX SEC filings page.
Moleculin Biotech, Inc. (MBRX) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Moleculin remains a development-stage business, with research spending and recurring cash outflows funded primarily by external financing.
In FY2025, the net loss of$33.6M exceeded the operating cash outflow of$22.7M , indicating that accounting charges and working-capital effects materially shaped the gap between reported earnings and cash use. With capital expenditures at$0 , free cash flow essentially matched operating cash flow, so reinvestment spending was not the main source of cash consumption.
Short-term coverage improved from 1.0x in FY2024 to 1.4x in FY2025, but the business still had no operating revenue to replenish those resources. Its reported liquidity comparison was 4.7 months of the latest annual operating outflow, describing the balance relative to that past outflow rather than establishing a forecast.
Research and development was
Financial Health Signals
We do not publish a peer-relative financial health score for Moleculin Biotech, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Moleculin Biotech, Inc. scores -15.92, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $206.0M against total assets of $22.1M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Moleculin Biotech, Inc. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.
Moleculin Biotech, Inc. reported a net loss of $33.6M while operations used $22.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Moleculin Biotech, Inc. generated $0 in revenue in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Moleculin Biotech, Inc.'s EBITDA was -$6.6M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Moleculin Biotech, Inc. reported a net loss of $6.5M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Cash & Balance Sheet
Moleculin Biotech, Inc. held $7.3M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Moleculin Biotech, Inc.'s quarterly ROE was -44.8% in Q3 2026: one quarter's net income over shareholder equity, not annualized. Against the prior quarter it is up 21.1 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
Moleculin Biotech, Inc. invested $4.5M in research and development in Q3 2026. This represents an increase of 20.1% from the same quarter a year earlier. Against the prior quarter it is down 17.7%.
Not reported for Q3 2026.
Not reported for Q3 2026.
MBRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| R&D Expenses | $4.5M+20.1% | $5.5M+51.4% | $5.4M+56.6% | $5.1M+14.9% | $3.7M-24.2% | $3.6M-12.0% | $3.4M-19.2% | $4.5M-32.8% |
| SG&A Expenses | $2.1M-1.5% | $2.1M+0.6% | $2.5M+0.4% | $2.4M+11.6% | $2.1M-1.2% | $2.1M+1.3% | $2.5M+3.5% | $2.2M-4.3% |
| Operating Income | -$6.6Mn/m | -$7.6Mn/m | -$7.9Mn/m | -$7.5Mn/m | -$5.9Mn/m | -$5.7Mn/m | -$5.9Mn/m | -$6.6Mn/m |
| EBITDA | -$6.6Mn/m | -$7.6Mn/m | -$7.9Mn/m | -$7.5Mn/m | -$5.9Mn/m | -$5.7Mn/m | -$5.9Mn/m | -$6.6Mn/m |
| Interest Expense | N/A | $78K | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Net Income | -$6.5Mn/m | -$7.6Mn/m | -$12.8Mn/m | $15.6M | -$25.4Mn/m | -$17.8Mn/m | -$5.9Mn/m | N/A |
| EPS (Basic) | -$9.59 | -$1.40n/m | -$3.54 | N/A | -$0.34 | -$28.68 | -$15.80 | $0.51 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EPS (Diluted), Diluted Shares (Avg).
MBRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $20.7M+1.9% | $21.1M-2.3% | $23.4M+11.2% | $22.1M+30.7% | $20.4M-13.0% | $21.6M-15.6% | $21.0M-31.9% | $16.9M-55.7% |
| Current Assets | $8.4M+6.7% | $8.7M-3.9% | $11.0M+17.4% | $9.7M+86.5% | $7.9M-32.1% | $9.1M-33.9% | $9.3M-50.7% | $5.2M-80.2% |
| Cash & Equivalents | $7.3M+8.7% | $7.3M-3.9% | $10.3M+33.7% | $8.9M+107.5% | $6.7M-28.7% | $7.6M-30.3% | $7.7M-54.1% | $4.3M-81.8% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $6.2M-86.8% | $9.5M-62.3% | $8.2M+13.3% | $7.1M+24.5% | $47.3M+690.1% | $25.2M+219.9% | $7.2M-22.0% | $5.7M-52.9% |
| Current Liabilities | $6.1M+8.0% | $9.3M+17.7% | $8.0M+15.5% | $6.9M+27.9% | $5.7M+1.6% | $7.9M+37.7% | $6.9M+27.5% | $5.4M-21.4% |
| Non-Current Liabilities | $112K-99.7% | $187K-98.9% | $218K-33.1% | $266K-25.7% | $41.6M+10564.4% | $17.3M+712.9% | $326K-91.5% | $358K-93.3% |
| Total Equity | $14.5Mn/m | $11.6Mn/m | $15.2M+10.1% | $15.0M+33.9% | -$26.9M-254.6% | -$3.6M-118.5% | $13.8M-44.8% | $11.2M-63.8% |
| Retained Earnings | -$233.0Mn/m | -$226.5Mn/m | -$218.8Mn/m | -$206.0Mn/m | -$221.6Mn/m | -$196.2Mn/m | -$178.3Mn/m | -$172.4Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
MBRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.0Mn/m | -$6.7Mn/m | -$6.1Mn/m | -$5.4Mn/m | -$7.2Mn/m | -$5.6Mn/m | -$4.6Mn/m | -$5.1Mn/m |
| Depreciation & Amortization | $8K-61.9% | $8K-72.4% | $8K-74.2% | $9K-71.0% | $21K-32.3% | $29K-6.5% | $31K-3.1% | $31K-11.4% |
| Stock-Based Compensation | $393K+29.7% | $436K+4.6% | $380K-21.6% | N/A | $303K-14.2% | $417K-7.9% | $485K-1.6% | N/A |
| Capital Expenditures | N/A | N/A | N/A | $0n/m | $0n/m | $0-100.0% | $0n/m | $0-100.0% |
| Free Cash Flow | N/A | N/A | N/A | -$5.4Mn/m | -$7.2Mn/m | -$5.6Mn/m | -$4.6Mn/m | -$5.1Mn/m |
| Investing Cash Flow | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Financing Cash Flow | $9.0M+41.6% | $3.6M-33.4% | $7.6M-4.8% | $7.5M+748600.0% | $6.4M+36.8% | $5.4Mn/m | $8.0Mn/m | $1K-100.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
MBRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -44.8% | -65.9% | -84.6%-41.8pp | 103.6% | N/A | N/A | -42.8%-17.1pp | N/A |
| Return on Assets | -31.3%+93.5pp | -36.2%+46.3pp | -55.0%-26.9pp | 70.3% | -124.8%-94.8pp | -82.5%-59.0pp | -28.1%-7.3pp | N/A |
| Current Ratio | 1.370.0x | 0.94-0.2x | 1.380.0x | 1.41+0.4x | 1.39-0.7x | 1.15-1.2x | 1.35-2.2x | 0.97-2.9x |
| Liabilities-to-Equity | 0.43 | 0.82 | 0.540.0x | 0.470.0x | N/A | N/A | 0.52+0.2x | 0.51+0.1x |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Moleculin Biotech, Inc. MBRX | FY2025 | $0 | -$33.6M | N/A | $8.4M | — |
| CalciMedica, Inc. CALC | FY2025 | N/A | -$29.6M | N/A | $8.1M | — |
| Tempest Therapeutics, Inc. TPST | FY2025 | N/A | -$26.3M | N/A | $6.1M | — |
| Soligenix, Inc. SNGX | FY2025 | N/A | -$11.1M | N/A | $5.6M | — |
| MetaVia Inc. MTVA | FY2025 | N/A | -$13.0M | N/A | $7.2M | — |
| Longeveron Inc. LGVN | FY2025 | $1.2M | -$22.7M | N/A | $6.1M | 54/100 |
Where Moleculin Biotech, Inc. Ranks
Frequently Asked Questions
Moleculin Biotech, Inc. (MBRX) reported $0 in total revenue for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
No, Moleculin Biotech, Inc. (MBRX) reported a net loss of $33.6M in fiscal year 2025.
Moleculin Biotech, Inc. (MBRX) had EBITDA of -$25.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Moleculin Biotech, Inc. (MBRX) has a return on equity of -223.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Moleculin Biotech, Inc. (MBRX) recorded an outflow of $22.7M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Moleculin Biotech, Inc. (MBRX) recorded an outflow of $22.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Moleculin Biotech, Inc. (MBRX) had $22.1M in total assets as of fiscal year 2025, including both current and long-term assets.
Moleculin Biotech, Inc. (MBRX) reported no capital expenditure during fiscal year 2025.
Moleculin Biotech, Inc. (MBRX) invested $15.9M in research and development during fiscal year 2025.
Moleculin Biotech, Inc. (MBRX) had a current ratio of 1.41 as of fiscal year 2025, which is considered adequate.
Moleculin Biotech, Inc. (MBRX) had a liabilities-to-equity ratio of 0.47 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Moleculin Biotech, Inc. (MBRX) had a return on assets of -151.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Moleculin Biotech, Inc. (MBRX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $8.4M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Moleculin Biotech, Inc. (MBRX) has no price-to-sales ratio at the moment: revenue is not positive (trailing 12 months to September 30, 2026). The market capitalization is $8.4M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Moleculin Biotech, Inc. (MBRX) held $8.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $22.7M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Moleculin Biotech, Inc. (MBRX) has an Altman Z-Score of -15.92, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Moleculin Biotech, Inc. (MBRX) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Moleculin Biotech, Inc. (MBRX) reported a net loss of $33.6M while operations used $22.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.